Now is the perfect time to buy these 3 healthcare stocks!

These three companies have stunning long-term return potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The outlook for the global economy may be bright, but it’s also uncertain. US interest rate rises, the US election and Brexit all loom on the horizon and could cause investors to move towards a more risk-off mentality. That’s a big reason why healthcare has huge appeal at the moment due to its defensive characteristics.

GlaxoSmithKline

For example, GlaxoSmithKline (LSE: GSK) is an exceptionally well-diversified business. It has three world-class divisions: consumer goods, vaccines and pharmaceuticals and this reduces its risk profile. It means that disappointment in one segment can be offset by strong performance elsewhere and with GlaxoSmithKline having a pipeline of around 40 potential treatments, the company offers excellent growth prospects, too.

In fact, it’s forecast to increase its earnings by 7% next year. This will boost its dividend coverage ratio, which will make its shareholder payouts more sustainable over the long run. On this topic, the company yields 4.7% from a dividend covered 1.3 times by profit. Although dividends aren’t due to rise over the next couple of years, beyond that GlaxoSmithKline’s growth potential indicates that shareholders will be rewarded through higher dividends in the long run.

Shire

While Glaxo offers top-notch income potential, Shire’s (LSE: SHP) yield of 0.4% holds little appeal for income seeking investors. However, this could change over the long run. A key reason for that is Shire’s combination with Baxalta, which is set to provide synergies and a more robust pipeline.

The deal is forecast to boost Shire’s bottom line, with growth of 18% forecast for next year. This puts Shire on a price-to-earnings growth (PEG) ratio of 0.7, which indicates that it offers strong growth at a very reasonable price.

This growth potential is set to catalyse Shire’s dividend payouts. They’re forecast to rise by 22% next year and while this doesn’t suddenly make Shire a top-notch income play, the fact that its dividends are covered 14.8 times by profit indicates that its shareholder payouts could be at the start of a period of significant growth.

Advanced Medical Solutions

As well as those two, Advanced Medical Solutions (LSE: AMS) is a worthy purchase right now. Its business model is very sound and consistent, with its focus on wound care providing a reliable financial outlook. In fact, in the last five years Advanced Medical Solutions has increased its earnings in every year, recording an annualised growth rate of 13% during the period.

Looking ahead, it’s expected to continue this growth with 7% forecast in each of the next two years. As with Shire, its yield of 0.4% lacks appeal for income-seeking investors, but with dividends being covered 8.2 times by profit, there’s scope for a rapid rise in shareholder payouts. As such, a 13% rise in dividends is due next year.

However, for investors who are only able to buy one of the three stocks discussed here, GlaxoSmithKline’s mix of growth and income marks it out as the most appealing buy for the long term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of Advanced Medical Solutions and GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Advanced Medical Solutions. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Shot of a young Black woman doing some paperwork in a modern office
Investing Articles

With an 8% dividend yield, I think this undervalued FTSE stock is a no-brainer buy

With an impressive yield and good track record of payments, Mark David Hartley is considering adding this promising FTSE share…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£9,500 in savings? Here’s how I’d try to turn that into £1,809 a month of passive income

Investing a relatively small amount into high-yielding stocks and reinvesting the dividends paid can generate significant passive income over time.

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

Dividend star Legal & General’s share price is still marked down, so should I buy more?

Legal & General’s share price looks very undervalued against its peers. But it pays an 8%+ dividend yield, and has…

Read more »

Investing Articles

Dividend shares: 1 FTSE 100 stock to consider buying for chunky shareholder income

This company’s ‘clean’ dividend record looks attractive to me and I’d consider buying some of the shares to hold long…

Read more »

Investing Articles

3 of my top FTSE 250 stocks to consider buying before April

Buying undervalued UK shares can be a great way to generate long-term wealth. Here, Royston Wild reveals a handful on…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »